IMRX
Immuneering Corp
NASDAQ: IMRX · HEALTHCARE · BIOTECHNOLOGY
$5.34
-0.84% today
Updated 2026-05-05
Market cap
$345.48M
P/E ratio
—
P/S ratio
563.62x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $10
Volume
0.9M
Immuneering Corp (IMRX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-43.10%
ROA
-26.10%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2019 | $1.92M | $-7.71M | 36.29% | -327.71% | -401.59% |
| 2020 | $2.31M | $-17.04M | 44.61% | -739.01% | -737.17% |
| 2021 | $2.08M | $-33.54M | 44.56% | -1,629.17% | -1,612.33% |
| 2022 | $316952.00 | $-50.51M | 50.11% | -16,325.77% | -15,937.29% |
| 2023 | $455.00 | $-53.47M | -167,942.42% | -12,837,997.14% | -11,752,004.84% |
| 2024 | $0.00 | $-61.04M | — | — | — |
| 2025 | $0.00 | $-56.02M | — | — | — |